Detalles de la búsqueda
1.
Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease.
Gastroenterology
; 161(6): 2041-2043.e1, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34391771
2.
Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease.
Front Immunol
; 13: 880190, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35464463
3.
The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders.
medRxiv
; 2021 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34909785
4.
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy.
Inflamm Bowel Dis
; 28(7): 1130-1133, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35397000
5.
Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.
HIV AIDS (Auckl)
; 3: 53-9, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22096407
6.
Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.
Arthritis Rheum
; 52(12): 4018-27, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16320350
7.
Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus.
Expert Opin Drug Saf
; 3(4): 273-8, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15268645
Resultados
1 -
7
de 7
1
Próxima >
>>